Higher Rated
Dukascopy
Capital at risk · T&Cs apply
Compare Trading 212 and Dukascopy side by side on fees, regulation, platforms and our expert ratings. Find out which broker suits your needs.
Trading 212
Dukascopy
Dukascopy is the better choice overall, scoring 3.7/5 vs 3.6/5 on BrokerRank's independent rating. On fees, Dukascopy offers lower spreads (0.1 pips).
See full side-by-side comparison belowOverall Rating
Dukascopy
3.6 vs 3.7
Lowest Fees
Dukascopy
0.5 vs 0.1 pips
Regulation
Tied
2 vs 2 licences
Min. Deposit
Trading 212
$1 vs $100
Trading 212
Dukascopy
WinnerTrading 212
Dukascopy
Trading 212 scores 3.57/5 while Dukascopy scores 3.71/5 in our independent rating.
Dukascopy edges ahead overall, but Trading 212 may suit traders who prioritise different features. Read our full reviews for a detailed breakdown. Scores are based on our transparent methodology.
Dukascopy scores higher overall on our independent rating system. Trading 212 holds a 3.6/5 rating vs Dukascopy's 3.7/5. The best choice ultimately depends on your trading style — see our full verdict above for a detailed breakdown.
Trading 212 offers spreads from 0.5 pips, while Dukascopy starts at 0.1 pips. Check the fees section above for a full breakdown.
Trading 212 requires a minimum deposit of $1. Dukascopy requires $100.
Trading 212 is regulated by FCA, CySEC, while Dukascopy holds licences from FCA, MAS.
Trading 212 supports Proprietary Web, Proprietary Mobile. Dukascopy supports Proprietary Web, Proprietary Mobile, MT4.
Yes, you can hold accounts at multiple brokers simultaneously. Many traders diversify across platforms to access different markets and tools.
Only 26% of Brokers Are Truly Fee-Free
BrokerRank Research — Hidden costs across 345 brokers
58% of Brokers Hold a Single Licence
BrokerRank Research — Regulation quality analysis
71% of Retail Traders Lose Money
BrokerRank Research — Loss rates across 50 EU brokers
76% of Brokers Use Proprietary Platforms
BrokerRank Research — MT4 vs MT5 vs proprietary
Trading involves risk. Past performance is not indicative of future results. Capital at risk. Full risk disclosure.